MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaChristine E. Ryan, Lindsey E. Roeker, Juliana M.L. Biondo et al.|Future Oncology|2022Cited by 35
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S. Davids, John C. Byrd, Jeff P. Sharman et al.|Blood Advances|2024Cited by 18